Ovid Therapeutics

An artists rendition of a seizure in the brain The brain is outlined in neon blue with the overactive neurons in glowing r

Ovid halts preclinical work, IV program after soticlestat fail

“Following Takeda's unexpected phase 3 results for soticlestat, we moved rapidly to focus our resources to preserve capital,” Ovid CEO Jeremy Levin said.

James Waldron Aug 13, 2024 9:15am

long shot miss basketball hoop fail shoot

Takeda flunks pivotal epilepsy tests but mulls path to market

Jun 17, 2024 8:50am

cash runway cash airplane extend deal earnings

Ovid sells some royalty rights to Takeda-partnered seizure drug

Oct 18, 2023 8:00am

Ovid snaps up Rock2 inhibitor from Sam Waksal-led Graviton

May 1, 2023 11:06am

Former Roche pharma head to be new Bayer CEO—Chutes & Ladders

Feb 10, 2023 9:30am

Layoff 'wave' not letting up amid oversaturation of biotechs

Mar 28, 2022 10:05am